Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-26T20:54:05.655Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment-resistant schizophrenia : the relationship between clozapine plasma concentration and clinical outcome

Published online by Cambridge University Press:  01 September 2022

I. Kammoun ,
R. Jouini ,
A. Aissa ,
R. Boukhchina ,
Y. Zgueb ,
E. Khelifa ,
U. Ouali ,
R. Jomli ,
F. Nacef  and
Z. El Hechmi
I. Kammoun
Affiliation:
Razi hospital, Psychiatry A Department, Manouba, Tunisia
R. Jouini
Affiliation:
Razi hospital, Psychiatry F, manouba, Tunisia Razi hospital, Psychiatry F Department, manouba, Tunisia
A. Aissa*
Affiliation:
Razi hospital, Psychiatry A Department, Manouba, Tunisia
R. Boukhchina
Affiliation:
Razi hospital, Psychiatry A Department, Manouba, Tunisia
Y. Zgueb
Affiliation:
Razi hospital, Psychiatry A Department, Manouba, Tunisia
E. Khelifa
Affiliation:
Razi hospital, Psychiatry F Department, manouba, Tunisia
U. Ouali
Affiliation:
Razi hospital, Psychiatry A Department, Manouba, Tunisia
R. Jomli
Affiliation:
Razi hospital, Psychiatry A Department, Manouba, Tunisia
F. Nacef
Affiliation:
Razi hospital, Psychiatry A Department, Manouba, Tunisia
Z. El Hechmi
Affiliation:
Razi hospital, Psychiatry F Department, manouba, Tunisia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Clozapine is highly effective in patients with treatment-resistant schizophrenia but, to ensure optimal clinical response it is important to optimize its use and this depends on adequate pharmacological monitoring.

Objectives

Evaluate the therapeutic response rate according to clozapine plasma concentration.

Methods

It was a cross-sectional, retrospective and analytical study, carried out over a period of six months, in the F and A psychiatry departments of the Razi hospital in Tunis, including patients followed for treatment-resistant schizophrenia and receiving clozapine. We evaluated the response to clozapine using the Brief Psychiatric Rating Scale (BPRS).

Results

The average age was 37.7 ± 9.4. The mean age of introduction of clozapine was 31 years and the mean time to its introduction was 9.3 years. Clozapine was administered as a single drug in 85% of cases. The mean dose of clozapine was 373 mg/day. The mean of clozapine plasma concentration was 386.5 ng/ml with a minimum of 89 ng/ml and a maximum of 913 ng/ml. The clinical response rate to clozapine was 25% with a BPRS good response threshold value of less than 35. Patients with clozapine levels above the conventional cut-off of 350 ng/ml (n=34) had a response rate of 34.6%. A response rate of 37% was observed in the group of patients with a clozapine plasma concentration interval of 200-350 ng/ml. There was no statistically significant difference in therapeutic response (p=0186)

Conclusions

Our study revealed a therapeutic response variation according to plasma clozapine concentration and showed the existence of a non-negligible and effective response rate.

Disclosure

No significant relationships.

Keywords

treatment-resistant schizophreniaclozapineclozapine plasma concentration
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S789
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.